Cargando…

Importance of Apolipoprotein A-I in Multiple Sclerosis

Jean-Martin Charcot has first described multiple sclerosis (MS) as a disease of the central nervous system (CNS) over a century ago. MS remains incurable today, and treatment options are limited to disease modifying drugs. Over the years, significant advances in understanding disease pathology have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardner, Lidia A., Levin, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654019/ https://www.ncbi.nlm.nih.gov/pubmed/26635608 http://dx.doi.org/10.3389/fphar.2015.00278

Ejemplares similares

Apolipoprotein A-I and Cancer
por: Zamanian-Daryoush, Maryam, et al.
Publicado: (2015)

Insulin Fused to Apolipoprotein A-I Reduces Body Weight and Steatosis in DB/DB Mice
por: Ardaiz, Nuria, et al.
Publicado: (2021)

Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms
por: Levin, Michael C, et al.
Publicado: (2014)

Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study
por: Faguer, Stanislas, et al.
Publicado: (2022)

Apolipoproteins: New players in cancers
por: He, Yingcheng, et al.
Publicado: (2022)

High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease
por: Gordon, Elizabeth M., et al.
Publicado: (2016)

Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation
por: Lu, Jing, et al.
Publicado: (2023)

Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer
por: Marinho, Aline T., et al.
Publicado: (2019)

Comparison of Mechanisms of Endothelial Cell Protections Between High-Density Lipoprotein and Apolipoprotein A-I Mimetic Peptide
por: Xu, Wenqi, et al.
Publicado: (2019)

Apolipoprotein Mimetic Peptides: A New Approach for the Treatment of Asthma
por: Yao, Xianglan, et al.
Publicado: (2012)

Apolipoprotein A-I mimetic peptides (ApoAI MP) improve oxidative stress and inflammatory responses in Parkinson’s disease mice
por: Jiang, Hongfang, et al.
Publicado: (2022)

Apolipoprotein A-I Mimetic Peptide L-4F Suppresses Granulocytic-Myeloid-Derived Suppressor Cells in Mouse Pancreatic Cancer
por: Peng, Meiyu, et al.
Publicado: (2020)

Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
por: Wei, Weipeng, et al.
Publicado: (2021)

Commentary: The apolipoprotein A-I mimetic peptide, D-4F, restrains neointimal formation through heme oxygenase-1 up-regulation
por: Li Volti, Giovanni, et al.
Publicado: (2017)

Comparison of serum apolipoprotein A-I between Chinese multiple sclerosis and other related autoimmune disease
por: Zhang, Bin, et al.
Publicado: (2010)

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis
por: Wang, Jiaying, et al.
Publicado: (2019)

Therapeutic Potential of Astrocyte Purinergic Signalling in Epilepsy and Multiple Sclerosis
por: Nobili, Paola, et al.
Publicado: (2022)

Apolipoprotein A-I Mimetic Peptides Prevent Atherosclerosis Development and Reduce Plaque Inflammation in a Murine Model of Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2010)

Cannabis for Neuropathic Pain in Multiple Sclerosis—High Expectations, Poor Data
por: Rudroff, Thorsten
Publicado: (2019)

Kv1.3 Channel Up-Regulation in Peripheral Blood T Lymphocytes of Patients With Multiple Sclerosis
por: Markakis, Ioannis, et al.
Publicado: (2021)

Nephrotoxicity in a Patient With Inadequate Pain Control: Potential Role of Pharmacogenetic Testing for Cytochrome P450 2D6 and Apolipoprotein L1
por: Tillman, Emma M., et al.
Publicado: (2020)

Celastrol Attenuates Multiple Sclerosis and Optic Neuritis in an Experimental Autoimmune Encephalomyelitis Model
por: Yang, Hongbin, et al.
Publicado: (2017)

Purinergic Receptors on Oligodendrocyte Progenitors: Promising Targets for Myelin Repair in Multiple Sclerosis?
por: Lecca, Davide, et al.
Publicado: (2021)

Tryptamine Attenuates Experimental Multiple Sclerosis Through Activation of Aryl Hydrocarbon Receptor
por: Dopkins, Nicholas, et al.
Publicado: (2021)

Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases
por: Hecker, Michael, et al.
Publicado: (2022)

Antibodies to the RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein A1 Colocalize to Stress Granules Resulting in Altered RNA and Protein Levels in a Model of Neurodegeneration in Multiple Sclerosis
por: Douglas, Joshua N., et al.
Publicado: (2016)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Pharmacokinetic Characteristics of Siponimod in Healthy Volunteers and Patients With Multiple Sclerosis: Analyses of Published Clinical Trials
por: Chaoyang, Chen, et al.
Publicado: (2022)

The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries
por: Gozzo, Lucia, et al.
Publicado: (2023)

Expression Pattern of Myelin-Related Apolipoprotein D in Human Multiple Sclerosis Lesions
por: Navarro, Ana, et al.
Publicado: (2018)

Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
por: Huisman, Eline, et al.
Publicado: (2017)

Protease-Activated Receptor-2 Deficiency Attenuates Atherosclerotic Lesion Progression and Instability in Apolipoprotein E-Deficient Mice
por: Zuo, Pengfei, et al.
Publicado: (2017)

Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis
por: Hostenbach, Stéphanie, et al.
Publicado: (2020)

Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab
por: Ottenlinger, Florian M., et al.
Publicado: (2016)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Isoquinoline Alkaloids and Indole Alkaloids Attenuate Aortic Atherosclerosis in Apolipoprotein E Deficient Mice: A Systematic Review and Meta-Analysis
por: Zhang, Yibing, et al.
Publicado: (2018)

Melatonin Therapy Modulates Cerebral Metabolism and Enhances Remyelination by Increasing PDK4 in a Mouse Model of Multiple Sclerosis
por: Ghareghani, Majid, et al.
Publicado: (2019)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yue, et al.
Publicado: (2020)

Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wu, Xin, et al.
Publicado: (2021)

Differential Expression of HERV-W in Peripheral Blood in Multiple Sclerosis and Healthy Patients in Two Different Ethnic Groups
por: Tarlinton, Rachael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mc57u7g11bme2dne0inndsmeh5